Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04262453
Other study ID # 2018-A02373-52
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 21, 2019
Est. completion date September 20, 2023

Study information

Verified date November 2023
Source Centre Hospitalier Sud Francilien
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective open-label, non-randomized, monocentric, cohort study, to assess the prevalence and severity of sleep apnea syndrome in patients treated for cancer of the upper aerodigestive tract. The patient follows a usual course of care including, at the end of the treatment of his cancer of the upper aerodigestive tract, screening for obstructive sleep apnea syndrome at 3 months and 6 months (Epworth score and ventilatory polygraphy)


Description:

Prospective open-label, non-randomized, monocentric, cohort study, to assess the prevalence and severity of sleep apnea syndrome in patients treated for cancer of the upper aerodigestive tract. Patients are included in the study when they are hospitalized for panendoscopy. Thereafter, it takes about 1 month to start any treatment. The duration of treatment is estimated at about 5 months (the longest regimen would be induction chemotherapy followed by surgery and adjuvant complementary treatment). After which the patient follows a usual course of care including, at the end of the treatment of his cancer of the upper aerodigestive tract, screening for obstructive sleep apnea syndrome at 3 months and 6 months (Epworth score and ventilatory polygraphy).


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date September 20, 2023
Est. primary completion date September 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - macroscopic lesion suggestive of a cancerous tumour of the upper aerodigestive tract (oral cavity, oropharynx, larynx, hypopharynx, cavum, cervical lymph node metastases with an occult primary cancer) - awaiting anatomopathological confirmation Exclusion Criteria: - history of cancer of the upper aerodigestive tract - history of known obstructive sleep apnea syndrome - cancer of the thyroid, salivary glands, nose and paranasal sinuses - patients under guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre Hospitalier Sud Francilien Corbeil-Essonnes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Sud Francilien

Country where clinical trial is conducted

France, 

References & Publications (4)

Faiz SA, Balachandran D, Hessel AC, Lei X, Beadle BM, William WN Jr, Bashoura L. Sleep-related breathing disorders in patients with tumors in the head and neck region. Oncologist. 2014 Nov;19(11):1200-6. doi: 10.1634/theoncologist.2014-0176. Epub 2014 Oct — View Citation

Gilat H, Shpitzer T, Guttman D, Soudry E, Feinmesser R, Bachar G. Obstructive sleep apnea after radial forearm free flap reconstruction of the oral tongue. Laryngoscope. 2013 Dec;123(12):3223-6. doi: 10.1002/lary.24125. Epub 2013 Apr 10. — View Citation

Huyett P, Kim S, Johnson JT, Soose RJ. Obstructive sleep apnea in the irradiated head and neck cancer patient. Laryngoscope. 2017 Nov;127(11):2673-2677. doi: 10.1002/lary.26674. Epub 2017 May 23. — View Citation

Loth A, Michel J, Giorgi R, Santini L, Rey M, Elbaum JM, Roux N, Giovanni A, Dessi P, Fakhry N. Prevalence of obstructive sleep apnoea syndrome following oropharyngeal cancer treatment: A prospective cohort study. Clin Otolaryngol. 2017 Dec;42(6):1281-128 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Occurence of obstructive sleep apnea syndrome Obstructive sleep apnea syndrome is defined by an apnea-hypopnea index greater than or equal to 15 per hour 3 months after the end of treatment for cancer of the upper aerodigestive tract
Secondary Delay in onset of obstructive sleep apnea syndrome after completion of cancer treatment Delay in onset of obstructive sleep apnea syndrome after completion of cancer treatment during the 6 months follow-up
Secondary Epworth score The Epworth auto-questionnaire, rated from 0 (better) to 24 (worse), assess day-time sleapiness. at 3 months and 6 months
Secondary Occurence of obstructive sleep apnea syndrome Obstructive sleep apnea syndrome is defined by an apnea-hypopnea index greater than or equal to 15 per hour 6 months after the end of treatment for cancer of the upper aerodigestive tract
See also
  Status Clinical Trial Phase
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT02540174 - Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment N/A
Completed NCT02869321 - Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Phase 4
Withdrawn NCT03955224 - Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer Phase 2
Recruiting NCT02439034 - Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304) Phase 2
Active, not recruiting NCT01788878 - Cancer of the Upper Aero-digestive Tract and Socio-professional Future N/A
Completed NCT00473564 - Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery N/A